A phase I clinical trial of VLA-1553 for Chikungunya virus infections.
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2017
At a glance
- Drugs VLA 1553 (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions
- 31 Aug 2017 According to a Valneva media release, the company intends to launch this trial in late 2017 or early 2018.
- 29 Mar 2017 According to a Valneva media release, this trial is expected to initiate in 2017.
- 29 Mar 2017 New trial record